Your browser is no longer supported. Please, upgrade your browser.
Ocular Therapeutix, Inc.
Index- P/E- EPS (ttm)-1.77 Insider Own4.66% Shs Outstand75.30M Perf Week-6.58%
Market Cap1.59B Forward P/E- EPS next Y-0.59 Insider Trans0.01% Shs Float63.18M Perf Month-5.74%
Income-96.00M PEG- EPS next Q-0.17 Inst Own55.50% Short Float9.23% Perf Quarter90.22%
Sales12.30M P/S129.32 EPS this Y-21.20% Inst Trans3.85% Short Ratio5.09 Perf Half Y131.83%
Book/sh-0.07 P/B- EPS next Y52.50% ROA-107.60% Target Price25.50 Perf Year327.08%
Cash/sh0.89 P/C22.53 EPS next 5Y- ROE- 52W Range3.78 - 24.30 Perf YTD-3.24%
Dividend- P/FCF- EPS past 5Y6.60% ROI-187.80% 52W High-17.57% Beta2.13
Dividend %- Quick Ratio3.50 Sales past 5Y40.50% Gross Margin81.80% 52W Low430.60% ATR1.28
Employees161 Current Ratio3.60 Sales Q/Q637.50% Oper. Margin- RSI (14)48.57 Volatility5.65% 6.20%
OptionableYes Debt/Eq- EPS Q/Q52.60% Profit Margin- Rel Volume0.64 Prev Close19.65
ShortableYes LT Debt/Eq- EarningsNov 05 AMC Payout- Avg Volume1.15M Price20.03
Recom2.00 SMA20-4.16% SMA506.29% SMA20086.34% Volume733,444 Change1.93%
Dec-28-20Downgrade H.C. Wainwright Buy → Neutral
Dec-17-20Initiated Berenberg Buy $27
Nov-13-20Reiterated Raymond James Strong Buy $15 → $25
Aug-10-20Reiterated H.C. Wainwright Buy $10 → $13
Mar-03-20Upgrade Raymond James Outperform → Strong Buy
May-21-19Reiterated H.C. Wainwright Buy $12 → $9
May-21-19Downgrade Raymond James Strong Buy → Outperform $11 → $5
May-21-19Downgrade Cowen Outperform → Market Perform $13 → $3
Dec-03-18Reiterated Cantor Fitzgerald Overweight $22 → $24
Nov-15-18Initiated Raymond James Strong Buy $10
Sep-07-18Initiated Piper Jaffray Overweight
Oct-24-17Initiated Guggenheim Buy $12
Jul-26-17Initiated H.C. Wainwright Buy $10
Jul-12-17Reiterated Cantor Fitzgerald Overweight $35 → $21
Jun-23-17Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-10-17Initiated Cantor Fitzgerald Overweight $35
Nov-15-16Reiterated RBC Capital Mkts Outperform $30 → $32
Aug-11-16Initiated JMP Securities Mkt Outperform
Feb-17-16Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-20-21 08:00AM  
Jan-07-21 08:00AM  
Jan-06-21 11:24AM  
Dec-28-20 08:00AM  
Dec-23-20 02:31PM  
Dec-22-20 08:45AM  
Dec-21-20 05:39AM  
Dec-15-20 09:47PM  
Dec-14-20 04:13PM  
Dec-11-20 10:55PM  
Nov-23-20 08:00AM  
Nov-11-20 09:00AM  
Nov-09-20 04:01PM  
Nov-06-20 02:13AM  
Nov-05-20 05:35PM  
Nov-04-20 08:00AM  
Oct-30-20 08:00AM  
Oct-29-20 12:35PM  
Oct-23-20 07:00AM  
Oct-22-20 07:32AM  
Oct-14-20 06:30AM  
Oct-13-20 05:01PM  
Oct-08-20 08:00AM  
Oct-07-20 08:00AM  
Oct-06-20 08:00AM  
Sep-29-20 08:00AM  
Sep-21-20 01:41PM  
Sep-10-20 07:00AM  
Sep-08-20 07:00AM  
Sep-04-20 12:52PM  
Sep-03-20 07:00AM  
Aug-07-20 08:45AM  
Aug-06-20 04:08PM  
Aug-05-20 03:30PM  
Jul-31-20 07:00AM  
Jul-29-20 12:33PM  
Jul-23-20 07:00AM  
Jul-17-20 07:30AM  
Jul-15-20 07:00AM  
Jun-15-20 06:38PM  
Jun-14-20 08:24PM  
Jun-12-20 06:13AM  
Jun-10-20 08:00AM  
May-29-20 08:00AM  
May-27-20 09:40AM  
May-25-20 10:00AM  
May-22-20 04:19PM  
May-20-20 07:30AM  
May-19-20 04:44PM  
May-12-20 07:00AM  
May-11-20 07:00AM  
May-09-20 11:30PM  
May-08-20 08:43AM  
May-01-20 12:30PM  
Apr-28-20 07:00AM  
Apr-13-20 08:00AM  
Mar-31-20 04:56PM  
Mar-12-20 07:45PM  
Mar-05-20 08:00AM  
Mar-03-20 07:30AM  
Feb-27-20 12:30PM  
Feb-25-20 08:00AM  
Feb-23-20 07:10AM  
Feb-18-20 08:10AM  
Feb-07-20 08:00AM  
Jan-13-20 01:34PM  
Dec-23-19 03:58PM  
Dec-06-19 02:20PM  
Dec-04-19 05:56PM  
Nov-26-19 08:00AM  
Nov-14-19 08:00AM  
Nov-12-19 08:15AM  
Nov-08-19 04:01PM  
Nov-05-19 08:00AM  
Oct-30-19 10:33AM  
Oct-15-19 11:38AM  
Oct-01-19 04:24PM  
Sep-26-19 08:00AM  
Sep-24-19 08:00AM  
Aug-29-19 08:00AM  
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel platform technology. The company markets ReSure Sealant, a hydrogel ophthalmic wound sealant to seal corneal incisions following cataract surgery. Its lead product candidate is DEXTENZA (dexamethasone ophthalmic insert), which has completed two Phase III clinical trials for the treatment of post-surgical ocular pain and inflammation, and allergic conjunctivitis; and DEXTENZA, which is in Phase III clinical trials for the treatment of dry eye diseases. The company also develops OTX-TP (intracanalicular travoprost insert), which is in Phase III clinical trials for the reduction of intraocular pressure (IOP) in patients with glaucoma and ocular hypertension; OTX-TIC, an intracameral travoprost implant, which is in Phase I clinical trials for the reduction of IOP in patients with moderate to severe glaucoma and ocular hypertension; OTX-TKI, an intravitreal tyrosine kinase inhibitor implant, which is in Phase I clinical trials for the treatment of wet age-related macular degeneration(AMD). Its various preclinical programs include OTX- BPI for the treatment of acute ocular pain; OTX-BDI to treat post-operative Pain, and inflammation and bacterial infection; OTX-CSI to treat dry-eye disease; and OTX-IVT, an intravitreal aflibercept implant for the treatment of wet AMD and other back-of-the-eye diseases. The company has strategic collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases. Ocular Therapeutix, Inc. was founded in 2006 and is headquartered in Bedford, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
PEACOCK BRUCEDirectorDec 03Option Exercise5.0925,000127,18025,000Dec 07 09:30 PM
SUMMER ROAD LLC10% OwnerOct 16Buy10.484374,5805,618,861Oct 20 04:06 PM
SUMMER ROAD LLC10% OwnerMay 19Buy5.50363,6361,999,9985,618,424May 21 04:15 PM
SUMMER ROAD LLC10% OwnerMar 24Buy4.8735,052170,7145,254,788Mar 24 09:42 PM
SUMMER ROAD LLC10% OwnerMar 23Buy4.6664,948302,3655,219,736Mar 24 09:42 PM
SUMMER ROAD LLC10% OwnerMar 20Buy4.529,10041,1195,154,788Mar 24 09:42 PM
SUMMER ROAD LLC10% OwnerMar 19Buy4.6340,900189,2245,145,688Mar 20 09:34 PM
SUMMER ROAD LLC10% OwnerMar 18Buy4.62344,9381,594,2005,104,788Mar 20 09:34 PM
SUMMER ROAD LLC10% OwnerMar 17Buy4.66550,0002,562,8904,759,850Mar 17 09:35 PM
SUMMER ROAD LLC10% OwnerMar 16Buy4.16194,262807,2174,209,850Mar 17 09:35 PM
SUMMER ROAD LLC10% OwnerMar 13Buy4.63210,800975,9834,015,588Mar 17 09:35 PM